Shots:
The P-III (INTRIGUE) evaluates the efficacy & safety of ripretinib vs sunitinib in patients with advanced GIST prior treated with imatinib at 122 active sites across 22 countries
The study did not meet its 1EPs of superiority in PFS. In patients with a KIT exon 11 primary mutation & in AP population, m-PFS (8.3mos. vs 7.0mos.) & (8.0mos. vs 8.3mos.), ORR (23.9% vs 14.6%) & (21.7% vs 17.6%), was well tolerated, patients experienced grade 3-4 TEAEs (41.3% vs 65.6%)
Qinlock is a switch-control TK inhibitor that inhibits KIT & PDGFRA mutated kinases & has been approved in the US for advanced GIST. The therapy is also approved as 4L treatment of GIST in Australia, Canada & 6 other countries
Ref: Businesswire | Image: Deciphera
